Much focus over the past few decades has been on the systolic phase of the cardiac cycle, yet it is becoming evident that more advanced therapies are warranted for the clinical management of heart failure, specifically diastolic dysfunction. A novel optimized approach in evaluating and managing diastolic dysfunction/ heart failure is required to evaluate and treat cardiac dysfunction. The proposed measures include the evaluation of the baseline functionality of the cardiac conduction system, Baseline E and A wave Measurement and Morphology  (BEAMM) and STRess-induced E and A wave Measurement and Morphology (STREAMM) with timing and variability taking into consideration of both macro and micro diastolic myocardial processes. Implementation of a management plan that includes echocardiographic optimization (ECHO-Op) and pharmaceutical optimization (PharmOp) into the current guideline recommendations for the evaluation and management of diastolic dysfunction/ heart failure is an additional goal. Clinical adoption of the proposed approach may lead to earlier identification of patients at risk of diastolic dysfunction/ heart failure as well as other associated cardiac symptoms and downstream pathological processes.